Company Information
CIN
Status
Date of Incorporation
26 July 2010
State / ROC
Mumbai / ROC Mumbai
Last Balance Sheet
31 March 2023
Last Annual Meeting
29 September 2022
Paid Up Capital
41,129,960
Authorised Capital
60,000,000
Directors
Mousumi Satyanarayana Vemula
Director
over 2 years ago
over 2 years ago
Gaurav Sharma
Director/Designated Partner
over 2 years ago
over 2 years ago
Past Directors
Urmila Devi Vemula
Director
over 13 years ago
over 13 years ago
Sathyanarayana Vemula
Director
over 15 years ago
over 15 years ago
Patents
An improved pharmaceutical formulation of tadalafil i.e., (6R-trans)-6-(l,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methylpyrazino-[1,2":l,6] pyrido[3,4-b]indole-l,4-dione" or a pharmaceutically acceptable salt thereof and process for the preparing thereof are disclosed.
The present invention relates to a pharmaceutical composition comprising simvastatin and ezetimibe and an organic acidifiers wherein particularly citric acid and ascorbic acid are omitted.
The present invention relates to pharmaceutical composition comprising Dabigatranetexile methyl sulfonate pellets without talc and Organic acid pellets.
A solid oral composition of teriflunomide comprising
(a) 1 % to 30 % w/w of teriflunomide;
(b) less than 0.5% w/w of an alkalinizing agent; and
(d) one or more pharmaceutical excipient(s);
wherein the composition is stable at 40°C and about 75% relative humidity for about 12 months
& the process of its prepar...
An immediate release composition comprising Sitagliptin hydrochloride and/or solvate and one or more pharmaceutical excipient(s), wherein the composition is prepared by wet granulation.
The present invention relates to reconstitutable, single use antidiabetic compositions which provide a single use composition comprising a) metformin or pharmaceutically acceptable salt as an extended release composition, b) optionally one or more antidiabetic agent(s) and optionally pharmaceutical acceptable excip...
A controlled release pharmaceutical composition for oral administration comprising a therapeutically effective amount of mirabegron or a pharmaceutically acceptable salt thereof, as an active ingredient, a hydrogel-forming polymer, as release controlling polymer, a colloidal agent, as a diluent and a pharmaceutical...
ABSTRACT
FILM COATED TABLET OF BEMPEDOIC ACID
The present invention relates to a pharmaceutical formulation comprising: a) bempedoic acid or pharmaceutically acceptable salts thereof admixed with monometal silicates, magnesium citrate, talc or starch and lubricants, optionally one or more pharmaceutically acceptab...
Registered Trademarks
[Class : 42] Scientific And Technological Services And
Research And Design Relating Thereto; Industrial
Analysis And Research Services For Pharmaceutical
[Class : 40] Treatment Of Materials
Charges
26 October 2017
Axis Bank Limited
5 Crore
19 July 2017
Axis Bank Limited
5 Crore
28 June 2017
Axis Bank Limited
2 Crore
04 November 2015
Bank Of India
3 Crore
30 March 2015
Bank Of India
1 Crore
30 March 2015
Bank Of India
2 Crore
09 November 2012
Bank Of Maharashtra
1 Crore
28 June 2021
Axis Bank Limited
17 Crore
16 September 2020
Standard Chartered Bank
28 Crore
28 June 2021
Axis Bank Limited
0
19 July 2017
Axis Bank Limited
0
26 October 2017
Axis Bank Limited
0
16 September 2020
Standard Chartered Bank
0
28 June 2017
Axis Bank Limited
0
30 March 2015
Bank Of India
0
04 November 2015
Bank Of India
0
09 November 2012
Bank Of Maharashtra
0
30 March 2015
Bank Of India
0
28 June 2021
Axis Bank Limited
0
19 July 2017
Axis Bank Limited
0
26 October 2017
Axis Bank Limited
0
16 September 2020
Standard Chartered Bank
0
28 June 2017
Axis Bank Limited
0
30 March 2015
Bank Of India
0
04 November 2015
Bank Of India
0
09 November 2012
Bank Of Maharashtra
0
30 March 2015
Bank Of India
0
Documents
Form DPT-3-04012021_signed
Supplementary or Test audit report under section 143-31122020
Consolidated Financial statements duly authenticated as per section 134 (Including Boards report, auditors report and other docu-31122020
Form AOC - 4 CFS-31122020
Form MGT-14-16102020-signed
CERTIFICATE OF REGISTRATION OF THE SPECIAL RESOLUTION CONFIRMING ALTERATION OF OBJECT CLAUSE(S)-20201016
Instrument(s) of creation or modification of charge;-14102020
Form CHG-1-14102020_signed
CERTIFICATE OF REGISTRATION OF CHARGE-20201014
Altered memorandum of association-29092020
Optional Attachment-(1)-29092020
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-29092020
Optional Attachment-(2)-29092020
Form DPT-3-03092020-signed
Form CHG-4-28072020_signed
Letter of the charge holder stating that the amount has been satisfied-28072020
Form DIR-12-31032020_signed
Notice of resignation;-30032020
Evidence of cessation;-30032020
Declaration of the appointee director, Managing director, in Form No. DIR-2;-30032020
Declaration by first director-30032020
Form AOC-4-15122019_signed
List of share holders, debenture holders;-13122019
Form MGT-7-13122019_signed
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-30112019
Statement of Subsidiaries as per section 129 - Form AOC-1-30112019
Certificate from a Chartered Accountant in practice for calculation of the average annual turnover during the relevant period in case of conversion is on the basis of such criteria.-01072019
Proof of Registered Office address(Conveyance/Lease deed/Rent Agreement along with the rent receipts) etc-01072019
Optional Attachment-(1)-01072019
